Abstract:

Ｏｂｊｅｃｔｉｖｅ：To investigate the impact of initial antiA/B antibody titer on clinical outcomes in ABOincompatible living donor kidney transplantation.
Ｍｅｔｈｏｄｏｌｏｇｙ：A series of forty ABOincompatible living kidney transplant recipients between September 2014 to November 2017 in West China Hospital were included in this study.According to initial antiA/B antibody titer,recipients were divided into lowantibody group (titer≤1∶16) (n=18) and high antibody group (n=22)(titer>1∶16).The baseline characteristics,change of antibody titer and clinical outcomes between both groups were compared.
Ｒｅｓｕｌｔｓ：The rebound of A/B antibody titer within 2 weeks after transplantation in all recipients was not more than 1∶16.The median followup time was 20 (3～42) months.There was no significant difference in the serum creatinine and eGFR of recipients in two years after transplantation between both groups (P>005).The oneyear graft and patient survival in lowantibody group and highantibody group were 944% vs 955%,and 100%  vs 100%,respectively (P>005).And one patient suffered from graft loss in each group because of hyperacute rejection.The incidence of rejection,infection,blood glucose and lipid metabolism,and the fatty liquefaction in wound were comparable between both groups (P>005).
Ｃｏｎｃｌｕｓｉｏｎ：Our data suggests the initial antiA/B antibody titer has no effect on outcomes of ABOincompatible kidney transplantation.

Key words: initial anti-A/B antibody titer, ABO-incompatible, living donor kidney transplantation, individualized preconditioning